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Abstract 
Background: The human Bri2 BRICHOS domain inhibits amyloid formation and toxicity and could be used as a 
therapeutic agent against amyloid diseases. For translation into clinical use, large quantities of correctly folded recom-
binant human (rh) Bri2 BRICHOS are required. To increase the expression and solubility levels of rh Bri2 BRICHOS it was 
fused to NT*, a solubility tag derived from the N-terminal domain of a spider silk protein, which significantly increases 
expression levels and solubility of target proteins. To increase the expression levels even further and reach the g/L 
range, which is a prerequisite for an economical production on an industrial scale, we developed a fed-batch expres-
sion protocol for Escherichia coli.
Results: A fed-batch production method for NT*-Bri2 BRICHOS was set up and systematically optimized. This gradual 
improvement resulted in expression levels of up to 18.8 g/L. Following expression, NT*-Bri2 BRICHOS was purified by 
chromatographic methods to a final yield of up to 6.5 g/L. After removal of the NT*-tag and separation into different 
oligomeric species, activity assays verified that different assembly states of the fed-batch produced rh Bri2 BRICHOS 
have the same ability to inhibit fibrillar and non-fibrillar protein aggregation as the reference protein isolated from 
shake flask cultures.
Conclusions: The protocol developed in this work allows the production of large quantities of rh Bri2 BRICHOS using 
the solubility enhancing NT*-tag as a fusion partner, which is required to effectively conduct pre-clinical research.
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Background
Alzheimer’s disease (AD) is the most common cause 
of dementia and belongs to a group of diseases that are 
characterized by the formation of deposits of specific 
proteins in amyloid fibrillar conformations [1]. Despite 
immense efforts from academia and the pharmaceutical 
industry, no disease-modifying treatment has been devel-
oped so far [2]. This is not only a problem for the patients 
and their families but also threatens to undermine the 
health care system at large since the progressive neu-
rodegenerative nature of AD inevitably results in long-
standing, severe decline in mental and physical status, 
and patients eventually require full-time attention [3]. 
This situation makes it necessary to investigate novel 
approaches to treat AD.
A large proportion of the human proteome has been 
found to contain amyloidogenic sequence motifs [4], sug-
gesting that there are specific endogenous mechanisms 
that protect amyloidogenic proteins from forming amy-
loid that otherwise would cause disease. The BRICHOS 
domain (named from its discovery in Bri2, chondromod-
ulin-1, and prosurfactant protein C) has emerged as the 
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domain that protects amyloidogenic protein segments 
from forming amyloid [5, 6]. The BRICHOS domains 
from different proteins can also prevent other amyloi-
dogenic proteins than their natural targets from forming 
amyloid, and this raised the possibility to harness BRI-
CHOS as a therapeutic strategy against amyloid diseases 
such as AD [7].
Mutations in the BRICHOS containing protein Bri2, 
which is associated with familial British and Danish 
dementias, give rise to the extended amyloidogenic pep-
tides ABri and ADan, respectively [8, 9]. Bri2 BRICHOS 
can prevent amyloid formation also of non-client pep-
tides, including amyloid β peptide (Aβ) and islet amy-
loid polypeptide (IAPP), associated with AD and type 
2 diabetes, respectively [10, 11]. For instance, Bri2 BRI-
CHOS prevents amyloid formation and neurotoxicity of 
the 42-residue Aβ42, the main amyloidogenic species in 
AD, in transgenic fruit flies and mice and prevents Aβ42 
neurotoxicity in mouse hippocampal slices in vitro [12–
15]. Moreover, recombinant human (rh) Bri2 BRICHOS 
passes the blood-brain barrier in wild-type mice, making 
parenteral administration of rh Bri2 BRICHOS an inter-
esting new potential treatment against AD [16, 17]. Such 
application of rh Bri2 BRICHOS would require industrial 
protein production and purification protocols that result 
in a homogenous product at a reasonable cost.
Rh BRICHOS can be produced on a laboratory scale 
using strategies involving the use of fusion partners [18]. 
However, it was found that rh Bri2 BRICHOS forms dif-
ferent assembly states, primarily monomers, dimers, and 
high molecular weight oligomers consisting of about 
20–30 subunits, which are difficult to resolve [15]. To cir-
cumvent this problem, we used a new production strat-
egy that stems from insights into the silk production 
process of spiders.
Spider silk proteins (spidroins) are aggregation prone 
and have been found to form amyloid-like fibrils, making 
their production and storage at very high concentrations 
until silk formation takes place a formidable challenge 
[19]. The spidroin N-terminal domain (NT) works as a 
solubility enhancer that enables the storage of spidroins 
and prevents precocious aggregation [20]. This function 
can be harnessed also for improved solubility and the 
production of non-spidroins. In particular, a designed 
mutant, NT*, can keep very aggregation-prone proteins, 
including amyloid forming proteins, proteases, and mem-
brane proteins, in solution [21–24]. NTs from widely dif-
ferent spidroins and spider species share the ability to 
improve solubility and increase recombinant production 
yields of aggregation prone proteins [23]. NT*, derived 
from the major ampullate spidroin from Euprosthenops 
australis spiders, was recently used as a tag to produce rh 
Bri2 BRICHOS and this enabled successful separation of 
the different assembly states [25]. Herein we investigate 
the feasibility to use Escherichia coli (E. coli) to produce 
NT*-Bri2 BRICHOS in bioreactors and study how the 
released target protein Bri2 BRICHOS acts as an inhibi-
tor of fibrillar and non-fibrillar protein aggregation.
Materials and methods
Expression of NT*‑Bri2 BRICHOS in E. coli bioreactor 
cultivations
A single colony of SHuffle T7 E. coli (New England Bio-
labs, Ipswich, USA) transformed with a pET-based plas-
mid encoding the gene for NT*-Bri2 BRICHOS [25] was 
used to inoculate 20 mL LB-medium (containing 50 mg/L 
kanamycin and 1% glycerol). The culture was incubated at 
30 °C and 220 rpm in a baffled flask overnight. Then, the 
culture was diluted 50 to 100 times into fresh medium to 
obtain an  OD600 of 0.05. In total 11 bioreactor cultiva-
tions were carried out in a Multifors 2 (Infors HT Basel, 
Switzerland) (Culture #1 to #5) or Minifors 2 (Infors HT, 
Basel, Switzerland) (Culture #6 to #11) with culture sizes 
in the range between 250–400 or 900–1200 mL, respec-
tively. The pH of all cultures was continuously adjusted 
to 7, by the addition of either 3 M  H3PO4 or 25%  NH3. 
The oxygenation level, pO2 was set to 30%, which was 
achieved by increasing the stirrer speed and/or the air-
flow rate. All cultivation media described hereafter were 
adopted from earlier reported recipes and were prepared 
by first autoclaving the main components in the reaction 
vessel, followed by separate addition of sterile stock solu-
tions of filtered glucose (700 g/L) and kanamycin (30 g/L), 
as well as autoclaved antifoam 204 (10%, Sigma Aldrich), 
trace metal solution (25×), and  MgSO4 (500 g/L), where 
applicable. The kanamycin concentration was 30 mg/L in 
all cultivations, and the initial concentration of antifoam 
204 was 0.01%.
In cultures #1 & 2, the expression of NT*-Bri2 BRI-
CHOS using complex media formulations including 
Lysogeny Broth (LB) and Terrific Broth (TB) were tested. 
These were grown continuously at 30 °C in a batch man-
ner and were induced by adding IPTG to 500 µM when 
 OD600 was still below 1. As a next step, the expression 
levels of NT*-Bri2 BRICHOS in semi-defined and defined 
media according to da Silva [26] (Batch medium adapted 
from experiment #4, feed medium from experiment #3 
without lactose), Korz [27], and Wyre [28] (semi-defined 
medium described in the paper) was tested (culture # 
3–5). After growing the cultures to  OD600 ≈ 30 (da Silva 
and Wyre) or 13 (Korz), they were induced by the addi-
tion of 33 µM IPTG. During the entire cultivation time, 
the temperature was held constant at 25  °C. In the next 
cultivation series, the medium formulation suggested by 
da Silva was used to identify the most optimal IPTG con-
centration to maximize the yield of soluble rh NT*-Bri2 
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BRICHOS. In this experiment, cultures #6–8 were 
grown at a constant temperature of 25  °C and induced 
with 50, 150, or 500 µM IPTG once  OD600 reached ≈ 30 
(≈1  L sized cultivations). Culture #9-11 is a replication 
of culture #7 (induction with 150  µM ITPG), with the 
exception that induction was implemented once  OD600 
reached 60. Furthermore, ~ 3 h before induction the tem-
perature was carefully increased to 27 °C, to enable faster 
growth, and then reduced to 25  °C when the cultures 
were induced with IPTG:
Independent of the induction point, exponential feed-
ing was initialized in all experiments once  pO2 levels 
increased suddenly, indicating that the carbon source 
contained in the batch medium was depleted. The feed-
ing rate was adjusted to an exponential feeding profile 
according to Eq. (1) [29]:
where F is the rate of feeding (L  h−1), s the concentration 
of the glycerol/glucose in the feed (g  L−1), µ the specific 
growth rate  (h−1), YX/S the biomass yield on the sub-
strate (g   g−1), m the specific maintenance coefficient (g 
 g−1   h−1), X the biomass concentration (g  L−1). The spe-
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and YX/S was 0.622 g  g−1 [26]. A summary of all essential 
cultivation parameters is found in Table 1.
After cultivation, the cells were harvested in a Sor-
vall LYNX 6000 (Thermo Scientific) centrifuge, using an 
F9-6 × 1000 LEX rotor at 4000×g for 20 min. Then, the 
cell pellet was re-suspended by gentle agitation at 4  °C 
in Buffer A (20 mM tris, pH 8.0), using 20 mL buffer per 
10  g wet cell weight. Cell resuspensions were stored at 
−20 °C.
Purification using immobilized metal ion affinity 
chromatography (IMAC)
A 50 mL cell resuspension was thawed and lysed using 
a cell disruptor (Constant Systems, Daventry, United 
Kingdom) at 1.35 kbar. Then DNAse I (Roche, Basel, 
Switzerland) was added to the lysed cells to a final 
concentration of 10  µg/mL, followed by incubation 
on ice for 30  min, and by centrifugation at 38,000×g 
in a Sorvall RC 6 + (Thermo Fisher Scientific) using 
an F21-8 × 50y rotor (4  °C for 30  min). After centrif-
ugation, the supernatant was filtered through a Fil-
tropur S 0.45 (Sarstedt, Nümbrecht, Germany). All 
subsequent purification steps were carried out on an 
Äkta Explorer liquid chromatographic system (GE 
Healthcare, Uppsala, Sweden) at 6  °C. The lysate was 
loaded onto 4 × 5  mL HiTrap Chelating HP columns 
Table 1 Summary of key parameters for the expression and purification of NT*Bri2 BRICHOS expressed in bioreactor cultivations in 
this study
a Expression level of NT*-Bri2 BRICHOS was estimated with SDS-PAGE. See also Additional file 1: Figures S2, S3
b Protein yield was calculated using  Abs280 and the protein specific extinction coefficient after NT*-Bri2 BRICHOS was eluted and dialyzed to remove imidazole
c Yield of NT*-Bri2 BRICHOS after purification
d Culture #9 was repeated 2 more times to estimate the batch-to-batch variation see Additional file 1: Table S1
e Dry cell weight for culture #9 was 82 g/L
f The expression level calculated by considering the % of NT*-Bri2 BRICHOS relative to the total protein content and the dry cell mass is 15.2 g/L
Culture #1 #2 #3 #4 #5 #6 #7 #8 #9d
Temperature (°C) 30 30 25 25 25 25 25 25 25
Medium LB TB da Silva Korz Wyre da Silva da Silva da Silva da Silva
Substrate in feed Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol
IPTG (µM) 500 500 33 33 33 50 150 500 150
OD600 induced 1 0.6 30 13 35 32 25 29 60
OD600 harvest 8.4 31 121 50 61 190 106 76 176
Induction time (h) 21 21 15 10 10 20 20 20 22
Total culture time (h) 26 26 39 39 39 47 47 47 49
Culture Size (mL) 400 400 325 274 307 910 900 907 1180
Wet Cell Weight (g/L) 13 32 197 58 81 200 120 82 214e
Expression level (g/L)a 0.53 0.82 2.1 2.1 2.7 7.9 7.9 6.2 18.8f
% of culture purified 100% 100% 25% 100% 50% 9.1% 11.6% 25% 7.1%
Purified (mg)b 37 73 40 70 92 133 428 510 540
Yield after purification (g/L)c 0.09 0.18 0.49 0.26 0.60 1.61 4.12 2.25 6.41
% of expression level 17.6% 22.3% 23.8% 11.9% 22.1% 20.4% 51.8% 36.4% 34.1%
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(GE Healthcare, Uppsala, Sweden) equilibrated with 
buffer A using a flow rate of 2.5  mL/min. Next, the 
proteins bound to the column were washed with buffer 
A containing 40 mM imidazole, before NT*-Bri2 BRI-
CHOS was eluted with buffer A containing 200  mM 
imidazole. After elution, the flow-through was re-
applied onto the columns, and NT*-Bri2 BRICHOS 
was washed and eluted in the same manner one more 
time. The combined eluate was subsequently dialyzed 
against 5 L buffer A overnight using a Spectra Por 
membrane (Spectrum Labs, Rancho Dominguez, USA) 
with a molecular weight cut-off between 6 and 8 kDa. 
All samples were stored at −20 °C.
Estimation of the NT*‑Bri2 BRICHOS expression level 
and the yield after purification
To estimate the expression levels of NT*-Bri2 BRI-
CHOS in the different cultures before harvest, a 
100 µL sample (undiluted culture #1; threefold diluted 
culture #4; fivefold diluted culture #5; tenfold diluted 
culture #3, and #6–9; 20-fold diluted culture #10–11) 
was centrifuged to pellet the cells. The supernatant 
was discarded, and the pellet was re-suspended into 
100 µl 8 M urea. 10 µL of each sample was loaded onto 
a 4–20% Mini-protean TGX stain-free precast SDS-
PAGE gel (Bio-Rad, Munich, Germany). To estimate 
the amount of protein in the samples, already puri-
fied NT*-Bri2 BRICHOS was used as standard: 0.24, 
0.48, 0.95, and 1.9  mg/ml unless noted otherwise. To 
create a standard curve, the standard bands were inte-
grated with ImageLab software (Biorad, Munich, Ger-
many), which correlated the band intensity to protein 
concentration.
The concentration of purified NT*-Bri2 BRICHOS 
was calculated using the protein specific extinction 
coefficient, Abs 0.1% (= 1  g/L) = 0.492, after meas-
uring the absorbance at 280  nm in triplicates. This 
method was also used to determine the concentration 
of the NT*-Bri2 BRICHOS standards used to estimate 
the expression level with SDS-PAGE.
The dry cell mass of culture #9–11 was determined 
by transferring 1 mL cell resuspensions (in triplicates), 
to already dried and weighed Eppendorf tubes. The 
cells were pelleted by centrifugation, the supernatant 
was removed, and the cell paste was dried at 65 °C for 
at least 24  h until a stable weight was obtained. This 
method enabled an alternative way to estimate the 
expression level of culture #9-11, by determining the 
% of NT*-Bri2 BRICHOS relative to the total cellular 
proteins, using GelAnalyzer 19.1, and considering that 
the protein fraction of the total dry cell weight is 55% 
[30].
Isolation of the different oligomeric species using size 
exclusion chromatography
IMAC (immobilized metal affinity chromatography) puri-
fied NT*-Bri2 BRICHOS was concentrated to 3.4  mg/
mL with a Vivaspin protein concentrator (10 kDa cut-off, 
GE Healthcare) at 4000×g and 4  °C. Then, the different 
rh NT*-Bri2 BRICHOS oligomeric species were isolated 
by size exclusion chromatography (SEC) using a Super-
dex 200 26/600 column (GE Healthcare, Uppsala, Swe-
den), which was equilibrated with Buffer B (20 mM  NaPi 
buffer pH 8.0 containing 0.2 mM EDTA), and an ÄKTA 
Explorer liquid chromatographic system (GE Healthcare, 
Uppsala, Sweden). The individual peaks corresponding 
to the differently sized oligomeric species were narrowly 
collected. Then, the rh NT*-Bri2 BRICHOS species were 
cleaved separately with 1: 600 thrombin (w/w, Merck) in 
a cold room overnight. After cleavage, the NT* tag was 
removed by reapplying the sample onto an IMAC col-
umn with buffer B (reverse IMAC), where rh Bri2 BRI-
CHOS was found in the flow-through, and the NT*-tag 
bound to the column was eluted with buffer B contain-
ing 200 mM imidazol. To polish the Bri2 BRICHOS spe-
cies, they were further purified with SEC one more time, 
using a Superdex 200 26/600 (for oligomer, tetramer, and 
dimer), or a Superdex 75 26/600 (for monomer) column 
(GE Healthcare, Uppsala, Sweden). The purified Bri2-
BRICHOS species were stored at −20 °C.
Citrate synthase thermal aggregation
The ability of the different rh Bri2 BRICHOS species to 
prevent non-fibrillar protein aggregation was assessed 
by suppressing thermo-denaturation of citrate synthase 
(CS). CS from porcine heart (Sigma-Aldrich, Germany) 
was diluted in 40  mM HEPES/KOH pH 7.5 to 600  nM 
and then incubated at 45  °C with and without differ-
ent concentrations of rh Bri2 BRICHOS oligomer or 
tetramer. The aggregation kinetics were monitored in 
triplicate using a microplate reader (FLUOStar Galaxy 
from BMG Labtech, Offenberg, Germany) by reading the 
apparent absorbance at 360 nm, as a measure of turbidity, 
under quiescent conditions.
Aβ42 monomer preparation and Thioflavin T assay
Aβ42 fused with a solubility tag (NT*) was expressed in 
BL21*(DE3) pLysS E. coli (B strain) cells (Novagen) and 
purified as described previously [23]. Briefly, NT*-Aβ42 
was purified by IMAC, and the NT* was released by 
TEV cleavage (1:100, w/w, in-house recombinantly pre-
pared). The crude cleaved sample was lyophilized and 
re-dissolved in 20 mM Tris pH 8.0 containing 7 M Gdn-
HCl. Pure Aβ42 monomers were isolated with a Super-
dex 75 column (GE Healthcare, Uppsala, Sweden) using 
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a 20  mM sodium phosphate pH 8.0 buffer containing 
0.2  mM EDTA. The Aβ42 monomer concentration was 
calculated with a protein specific extinction coefficient of 
1 424  M−1  cm−1 for  (A280-A300).
For testing the activities of rh Bri2 BRICHOS species 
against Aβ42 fibril formation, 80 µL reaction solution 
containing 3  µM Aβ42 monomers, 10  µM Thioflavin T 
(ThT) and different concentrations of Bri2 BRICHOS 
species at molar ratios 0, 10, 50, and 100% relative to 
Aβ42 were added to each well of half-area 96-well micro-
plates (Corning Glass 3881, USA). The fluorescence was 
recorded using a 440  nm excitation filter and a 480  nm 
emission filter (FLUOStar Galaxy from BMG Labtech, 
Offenberg, Germany) under quiescent conditions at 
37  °C. Aggregation traces are averages of four replicates 
for all the experiments. For comparing the activities of 
each Bri2 BRICHOS species, the aggregation half time 
τ1/2 and the maximal growth rate rmax were extracted by 
an empirical sigmoidal Eq. (2) [25, 31]:
where A is the amplitude and F0 the base value.
Stability of Bri2 BRICHOS oligomers and dimers
Rh Bri2 BRICHOS oligomers (10  μM) and mono-
mers (5  μM) expressed in the bioreactor were incu-
bated in 20 mM sodium phosphate pH 8.0 with 0.2 mM 
EDTA overnight at 37℃, and samples were analyzed by 
SDS-PAGE under native, reducing, and non-reducing 
conditions.
Results
Expression and purification of NT*‑Bri2 BRICHOS 
in the bioreactor
A typical yield of NT*-Bri2 BRICHOS is 80 mg/L when 
purified with IMAC after expression in a shake flask type 
cultivation, using LB medium and inducing with 500 µM 
IPTG when the  OD600 is below 1. This is comparable to 
the yield of purified NT*-Bri2 BRICHOS produced by 
bioreactor culture #1, which essentially follows this sim-
ple shake flask expression protocol (a summary of all the 
essential parameters of each culture is summarized in 
Table 1). Notably, the same expression protocol, but using 
the richer TB medium doubled the yield to 180  mg/L 
(culture #2). Because we did not expect any significant 
improvement by optimizing the expression protocol 
using these complex media in terms of the cell density, we 
tested more sophisticated formulations, which included 
two semi-defined and one defined medium, originally 
described by da Silva, Korz, and Wyre (Culture #3, #4, 
and #5, respectively) [26–28]. Since native Bri2 BRI-
CHOS has one disulfide bond and tends to form higher-
order assemblies [25], we proceeded with a cultivation 
(2)F = F0 + A/(1+ exp[rmax(τ1/2 − t)])
strategy that minimizes the cellular stress level to maxi-
mize the expression levels [28, 32]. Thus, instead of fast 
growth at 37  °C before induction, we aimed to keep the 
temperature at a constant level of 25  °C throughout the 
entire cultivation. Furthermore, it is known that induc-
tion with high IPTG concentrations inhibits the expo-
nential growth of E. coil [33], and therefore we induced 
with only 33 µM IPTG in the subsequent cultures.
Reaching  OD600 1.2 after 17 h at 25 °C, cells cultivated 
in the defined medium suggested by Korz exhibited the 
slowest growth in direct comparison to the semi-defined 
formulations by Wyre and da Silva  (OD600 was 3.6 and 
11.6, respectively). After a total culture time of 39 h, the 
da Silva-medium yielded an  OD600 of 120, Wyre-medium 
an  OD600 of 61, and Korz-medium an  OD600 of 50. Even 
though the medium according to da Silva yielded the best 
results in terms of cell density, after purification the yield 
was 0.6  g/L soluble NT*-Bri2 BRICHOS for Wyre and 
0.5 g/L for da Silva medium (Table 1). This is an improve-
ment of the NT*-Bri2 BRICHOS yield by a factor of two 
compared to the preceding cultivations. However, sub-
stantial impurities were seen for the NT*-Bri2 BRICHOS 
produced using the da Silva medium (Additional file  1: 
Figure S1). Nevertheless, we decided to express NT*-Bri2 
BRICHOS one more time in medium from da Silva, due 
to its high potential for dense microbial growth. To test 
whether the expression level could be improved further, 
we induced with 50, 150, and 500 µM IPTG once  OD600 
reached 30 (culture #6, #7, and #8, respectively). Accord-
ing to the  OD600 measured before culture harvest and 
the wet cell mass after harvest, there is a possible nega-
tive correlation between the amount of IPTG used to 
induce the culture and the final cell mass, however, the 
expression levels of NT*-Bri2 BRICHOS were compa-
rable (Table  1). Induction with 150  µM IPTG resulted 
in an expression level of 7.9 g/L, whereas the expression 
levels of the cultures induced 50 µM and 500 µM IPTG 
were 7.9 and 6.2  g/L, respectively. Considering that the 
highest protein yield after purification (4.1  g/L) was 
achieved with the culture induced with 150  µM IPTG, 
we attempted to improve this further, by changing the 
point of induction. Repeating the protocol of culture #7 
but inducing expression at  OD600 60 instead of around 
30 increased the expression level additionally by a fac-
tor of two to 18.8 g/L (culture #9, Fig. 1). Purification of 
NT*-Bri2 BRICHOS from this batch using IMAC yielded 
6.4  g/L, which is the highest achieved in this study. 
Finally, to assess the reproducibility of this process, two 
more cultivations were performed replicating the condi-
tions of culture #9. This time, the expression level was 
10.3  g/L (culture #10) and 6.5  g/L (culture #11), which 
yielded 3.45 and 2.25  g/L of NT*-Bri2 BRICHOS after 
purification (Additional file 1: Table S1).
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Isolation of monomer, dimer, and oligomeric species 
of NT*‑Bri2 BRICHOS
NT*-Bri2 BRICHOS is prone to form different oligo-
meric species, that differ with respect to their potency 
to inhibit amyloid formation and non-fibrillar protein 
aggregation, respectively [25]. To enable a more precise 
investigation of NT*-Bri2 BRICHOS produced in the 
bioreactor, the protein was separated into monomers, 
dimers, and higher order oligomers with size exclusion 
chromatography (Fig. 2a). From this experiment interest-
ingly four peaks were resolved, whereas three peaks are 
isolated from NT*-Bri2 BRICHOS expressed in shake 
flasks, corresponding to peaks I, III, and IV in Fig. 2a. The 
additional peak (II) corresponds to a tetramer (Fig.  3). 
The individual NT*-Bri2 BRICHOS species were cleaved 
with thrombin and the rh Bri2 BRICHOS species were 
separated from the NT*-tag (containing a  His6-tag) by 
reverse IMAC. Finally, the rh Bri2 BRICHOS species 
were concentrated before isolation with SEC to obtain 
pure oligomeric, tetrameric, dimeric, and monomeric 
species (Fig. 2b, C) and their prolonged stability at 37 °C 
was confirmed (Additional file 1: Figure S4).
Inhibition of amyloid fibril formation and non‑fibrillar 
protein aggregation
To assess if differences exist between rh Bri2 BRI-
CHOS expressed in the shake flask or using a bioreac-
tor, the inhibitory effect of rh Bri2 BRICHOS against 
Fig. 1 Bioreactor production of rh Bri2 BRICHOS. a Fed-batch cultivation (Culture #9). After 28 h, the oxygen demand suddenly decreased, and 
the feeding was initiated. b Estimation of expression level by SDS-PAGE. A sample from the cultivation 19 h and 21 h after induction was diluted 
10-times. S1–S4 served as standards to estimate the concentration of NT*-Bri2 BRICHOS.  S1 0.24 mg/mL;  S2 0.48 mg/mL;  S3 0.95 mg/mL;  S4 1.9 mg/
mL. c IMAC purification. L: cell lysate; D: pellet after centrifugation; E1: IMAC eluate; FT1: Flow-through round 1; E2: IMAC eluate after re-loading FT1; 
FT2: Flow-through round 2
Fig. 2 Size exclusion chromatography of NT*-Bri2 BRICHOS and Bri2 BRICHOS after cleavage with thrombin and reverse IMAC. a Chromatogram of 
NT*-Bri2 BRICHOS using a Superdex 200 column to isolate the individual oligomeric species (monomer: peak IV, dimer: peak III, tetramer: peak II and 
higher oligomers: peak I). The individual species were then cleaved with thrombin to remove the NT*-tag and Bri2 BRICHOS was separated from 
the NT*-tag using reverse IMAC. b Chromatograms of oligomeric (I), tetrameric (II) and dimeric (III) Bri2 BRICHOS using a Superdex 200 column. c 
Chromatogram of monomeric (IV) Bri2 BRICHOS using a Superdex 75 column
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non-fibrillar aggregation of heated citrate synthase and 
amyloid fibril formation of Aβ42 was tested. In the assay 
involving citrate synthase, rh Bri2 BRICHOS oligomers 
showed a dose dependent activity against non-fibrillar 
protein aggregation and at a ratio of 1:2 (0.6 µM citrate-
synthase vs 1.2 µM BRICHOS), the aggregation was com-
pletely inhibited (Fig.  4), similar to the capacity of the 
Bri2 BRICHOS oligomers produced in shake flasks [25]. 
The rh Bri2 BRICHOS tetramers did not show any inhibi-
tory effects on thermo-induced citrate synthase aggrega-
tion, comparable to the lack of activity seen for monomer 
and dimer obtained from shake-flask expressed rh Bri2 
BRICHOS [25]. These observations support that Bri2 
BRICHOS large oligomers are required for general chap-
erone activity against amorphous protein aggregation.
Next, the activities of different species against Aβ42 
fibril formation were assessed using a ThT based assay. 
The different rh Bri2 BRICHOS species showed a dose-
dependent influence on Aβ42 fibrillation traces indicated 
by ThT fluorescence (Fig. 5). Among them, the dimer and 
tetramer were the most efficient species, in particular 
the dimer, as they showed the most prominent effect on 
increasing τ1/2 (time until half maximum fluorescence is 
reached) and decreasing rmax (the maximum growth rate) 
(Fig. 6). Further, the dimeric rh Bri2 BRICHOS lowered 
the final fluorescence intensity drastically, whereas the 
tetramer only showed minor effects on the final inten-
sity at the highest concentration tested (Fig.  7). The 
effects on Aβ42 fibril formation and final intensity for the 
tetramer may in part be due to the presence of dimers in 
the tetramer fraction. The oligomers and monomers did 
not reduce the final ThT intensity. Thus, according to 
the increase in τ1/2 , the reduction of maximum rate and 
the final ThT intensity, the relative inhibition efficiencies 
against Aβ42 fibril formation are dimer > tetramer > mon-
omer > oligomer. Our previous data on the rh Bri2 BRI-
CHOS species produced in shake flasks [25], in terms of 
Fig. 3 SDS-PAGE analysis of the rh Bri2 BRICHOS species isolated 
with size exclusion chromatography. E1 indicates the eluted NT*-Bri2 
BRICHOS from IMAC. Oligomer (oli), dimer (dim) and monomer (mon) 
fractions labeled with ‘cleavage’, correspond to the SEC isolated 
NT*-Bri2 species after overnight thrombin cleavage. After individual 
cleavage, each species was purified with reverse IMAC to remove the 
NT*-tag, followed by SEC, to isolate the oligomer, tetramer, dimer, 
and monomers. The individual species were collected and analyzed 
by SDS-PAGE under reducing (red.) and non-reducing (non-red.) 
conditions. M indicates the protein ladder. Noteworthy, the tetramer 
(tet.) fraction also contains a small amount of hexamer, which could 
have formed after collection of the corresponding peak eluted from 
SEC. The dimer band visible in the same fraction could either be a 
contamination from the adjacent dimer peak or emanate from a 
non-covalent tetramer
Fig. 4 Activities of rh Bri2 BRICHOS oligomers and tetramers against citrate synthase in a turbidity assay. a Oligomeric (oli) species inhibit citrate 
synthase aggregation, whereas this effect is not seen for tetramers (tet). b Concentration dependent effect of rh Bri2 BRICHOS oligomers and 
tetramers on citrate synthase aggregation
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activity against Aβ42 fibril formation, showed that the 
dimer had a τ1/2 of ~ 12 h, while ~ 10.5 h and ~ 5.5 h was 
achieved for the monomer and oligomer, respectively, 
giving the following efficiency order dimer > mono-
mer > oligomer. Compared to the rh Bri2 BRICHOS spe-
cies from shake flask cultures, the bioreactor produced 
rh Bri2 BRICHOS species thus showed similar or better 
efficiency in inhibition of Aβ42 fibril formation.  
Discussion
To use recombinant proteins for medical or biotech-
nological applications, the production needs to be 
scalable and the typical expression levels need to be in 
Fig. 5 Time dependent fluorescence traces of Thioflavin-T to test the inhibition efficiency of rh Bri2 BRICHOS monomers (a), dimers (b), tetramers 
(c), and higher order oligomers (d) against fibril formation of Aβ42
Fig. 6 The aggregation half time τ1/2 (a) and the maximal growth rate rmax (b) of rh Bri2 BRICHOS species against Aβ42 fibril formation
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the high g/L scale to be economical [34, 35]. E. coli is 
a favorite workhorse for the production of biopharma-
ceuticals and is used for the production of about 30% 
of all clinically approved proteins [36], but a frequently 
occurring drawback of this heterologous host is the for-
mation of inclusion bodies [28, 35, 37, 38]. To increase 
the yield and improve the solubility of otherwise aggre-
gation prone peptides, the NT* domain was developed. 
NT* is a solubility tag that has successfully been used 
to increase the yield of several proteins up to a factor 
of eight, compared to other commonly used solubility 
tags [21, 23]. These results were obtained with shake 
flask cultivations using E. coli, hence the next logical 
step was to employ the NT*-domain for protein expres-
sion in a high-cell density bioreactor cultivation. In this 
study, we attempted to express and purify the rh Bri2 
BRICHOS domain on a g/L scale employing the NT*-
tag. Rh Bri2 BRICHOS has emerged as an interesting 
biopharmaceutical candidate for treating AD, as the 
domain is a potent inhibitor of Aβ42 amyloid fibril for-
mation and in particular its associated neurotoxicity 
in vitro, in hippocampal slice preparations ex vivo, and 
in Drosophila models in vivo [15]. In addition, rh Bri2 
BRICHOS passes the blood-brain barrier [16].
To increase the expression yield of rh Bri2 BRICHOS 
compared to standard shake flask cultivations, we rea-
soned that the medium composition and feeding with a 
suitable carbon source are key elements to obtain a high 
cell density culture, in addition to proper oxygen supply 
and pH control. Accordingly, three previously suggested 
medium formulations that are supposed to support 
cell densities higher than 70  g/L (dry cell weight) were 
tested for culturing E. coli SHuffle cells in a bioreactor 
using a fed-batch setup [26–28]. Interestingly, this initial 
experiment revealed that an  OD600 above 100 was only 
obtained for the medium formulation described by da 
Silva et al., why we chose this medium for all subsequent 
cultivations.
Furthermore, the influence of different IPTG concen-
trations for induction on the cell density at harvest and 
the expression level was tested (Table 1, culture #3, 6, 7, 
and 8). We observed a fourfold increase in expression 
level as the IPTG concentration was increased from 33 to 
50 µM, however, the cell density at harvest was severely 
decreased if the IPTG concentration was 150  µM or 
Fig. 7 Final intensity of aggregation traces of the rh Bri2 BRICHOS monomers (a), dimers (b), tetramers (c), and higher order oligomers (d) against 
Aβ42 fibril formation
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higher, but without elevating the expression level. This 
confirms the importance of reducing and optimizing the 
inducer concentrations, to minimize cellular stress fac-
tors, as previously suggested for improved expression 
levels of soluble protein [28, 32]. Induction with 150 µM 
IPTG at  OD600 of 30 resulted in an NT*-Bri2 BRICHOS 
expression level of 7.9 g/L. A minimal adjustment of this 
protocol by inducing protein expression at  OD600 of 60 
instead, elevated the expression level to 18.8 g/L (15.2 g/L 
if estimated from the dry cell weight), which competes 
with the highest reported recombinant protein expres-
sion levels for E. coli (Table 2) [26, 28, 37–44]. The caveat 
with this protocol is the high batch-to-batch variation, as 
repeating the exact cultivation conditions of #9 (culture 
#10 and #11) has not consistently resulted in expression 
levels of > 15  g/L. Nevertheless, at least 6  g/L NT*-Bri2 
BRICHOS can be expected (Additional file 1: Table S1).
Purification of Bri2-BRICHOS was executed in the 
same manner as previously described [25], and involved 
isolation of NT*-Bri2 BRICHOS with IMAC. The high-
est obtained yield after purification was 6.7 g/L (culture 
#9), which corresponds to 34% of the expressed protein. 
The main problem we faced during purification was that 
a large portion of NT*-Bri2 BRICHOS was found in the 
pellet after cell lysis/centrifugation and that the protein 
did not fully bind to the column and was to a large extent 
present in the flow-through (Fig. 1c). Therefore, the flow-
through was reapplied to increase the yield, but still, 
a significant fraction was not recovered, which means 
that the yield most likely can be improved by additional 
optimizations.
Another relevant question that we wanted to inves-
tigate was whether the protein aggregation inhibition 
profiles of bioreactor produced rh Bri2 BRICHOS are 
comparable to previously published data for the shake 
flask-produced protein. To answer this, after removal 
of the NT*-tag with thrombin, rh Bri2 BRICHOS 
was separated into the individual oligomeric species 
using SEC. Interestingly, we were not only able to iso-
late monomers, dimers, and higher order oligomers 
but also tetramers, a species that we were not able to 
purify from our previous shake-flask preparations. The 
tetramer was predominantly formed after the removal 
of NT* from the NT*-Bri2 BRICHOS dimer. So far, we 
do not know what can trigger the transformation of 
the tetramer from the dimer, but the high concentra-
tion is probably an explanation as the Bri2 BRICHOS 
oligomerization process is sensitive to increased con-
centration [31]. Also, we cannot exclude the possibil-
ity that the composition of the cultivation medium, e.g. 
metals, could have potential effects on the equilibrium 
of the different species, and future work is necessary 
to elucidate the exact mechanisms behind this behav-
ior. Nevertheless, in accordance with earlier results, CS 
aggregation was only inhibited by the presence of Bri2 
BRICHOS oligomers. Likewise, the inhibition profile 
of Bri2 BRICHOS against Aβ42 amyloid formation is 
comparable, suggesting that the chaperoning capacities 
against fibrillar amyloid aggregation and non-fibrillar 
Table 2 Summary of some of the highest reported expression levels of recombinant protein using E. coli 
n.r. – not reported. IB – inclusion bodies
a Refers to the buffer used to recover the proteins after cell lysis
b The exact identity of the model cytoplasmic protein is not reported
c Kopp et al. describe a repetitive fed-batch protocol, in which the expression level is increased after every round. The value here represents the expression level after 
the first round of fed-batch to make it comparable to the other values reported here. The highest expression level that Kopp et al. reported was 35.5 g/L
d Highest expression level reported. The highest concentration of soluble protein in the same study was 6 g/L








surface protein A from Erysipelothrix rhusiopathiae 42 6.4 n.r n. r da Silva et al. [26]
tilapia insulin-like growth factor-2 7 9.7 1.99e 5 M urea (IB) Hu et al. [37]
human soluble B lymphocyte stimulator 18 3.8 n. r n. r Zhang et al. [39]
model cytoplasmic  proteinb n. r 17.6c n.r 0.1 M Tris–HCl Kopp et al. [40]
chemotaxis protein CheY fused to green fluorescent 
protein from Aequorea victoria
n.r 12.0d n.r Bug Buster reagent Wyre et al. [28]
human leptin 16 9.7 3.98e 8 M urea (IB) Jeong et al. [41]
human interleukin 6 n.r 8.5 n.r n. r Tae et al. [38]
phenylalanine dehydrogenase mutant fromTramiti-
chromis intermedius
40 n.r 4.6 20 mM  KPi Zhao et al. [42]
NT*‑Bri2 BRICHOS 29.6 18.8 6.5 20 mM Tris‑ HCl This study
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amorphous aggregation of Bri2 BRICHOS are inde-
pendent of the expression and purification protocol.
Conclusion
In this study, we establish an expression protocol of 
the human small heat shock protein chaperone domain 
Bri2 BRICHOS. Optimization of the process resulted in 
an expression level of up to 18.8  g/L, which is among 
the highest protein expression levels reported for E. 
coli. The high yield is likely attributed to the use of the 
NT*-tag, which drastically increases the solubility and 
expression levels of certain peptides and proteins. Since 
rh Bri2 BRICHOS is a promising candidate for treating 
AD, the protocol described in this paper is important to 
enable future research and successful translation into 
clinical trials.
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